Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EHP-101 in Diffuse Cutaneous Systemic Sclerosis
NCT04166552Phase 2Suspended
- Sponsor
- Emerald Health Pharmaceuticals Inc.
- Start
- Jun 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of etrinabdione in diffuse cutaneous systemic sclerosis (dcSSc), sponsored by Emerald Health Pharmaceuticals Inc.. Started Jun 2020; status: suspended.
02
Drugs
etrinabdione
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT04166552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04166552.